Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 30 | 2023 | 3186 | 3.230 |
Why?
|
Kidney Neoplasms | 28 | 2023 | 4282 | 2.750 |
Why?
|
Pelvis | 9 | 2020 | 737 | 1.590 |
Why?
|
Posture | 6 | 2020 | 955 | 1.050 |
Why?
|
Spine | 5 | 2020 | 1134 | 0.950 |
Why?
|
Gait | 4 | 2020 | 823 | 0.830 |
Why?
|
Neoplasms | 22 | 2023 | 22343 | 0.820 |
Why?
|
Cerebral Palsy | 4 | 2018 | 481 | 0.780 |
Why?
|
Immunotherapy | 11 | 2023 | 4749 | 0.720 |
Why?
|
Imaging, Three-Dimensional | 9 | 2020 | 4047 | 0.650 |
Why?
|
Scoliosis | 4 | 2020 | 793 | 0.640 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2022 | 790 | 0.620 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 11872 | 0.600 |
Why?
|
Salvage Therapy | 2 | 2018 | 1274 | 0.570 |
Why?
|
Nephritis, Interstitial | 1 | 2018 | 157 | 0.560 |
Why?
|
Antineoplastic Agents | 8 | 2021 | 13639 | 0.550 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2022 | 2185 | 0.540 |
Why?
|
Kyphosis | 2 | 2020 | 252 | 0.530 |
Why?
|
Walking | 4 | 2020 | 1201 | 0.490 |
Why?
|
Down Syndrome | 3 | 2018 | 916 | 0.490 |
Why?
|
Patient Positioning | 3 | 2018 | 332 | 0.480 |
Why?
|
Purines | 1 | 2018 | 616 | 0.460 |
Why?
|
Bone and Bones | 2 | 2020 | 2559 | 0.460 |
Why?
|
Aminopyridines | 1 | 2018 | 576 | 0.450 |
Why?
|
Physical Fitness | 1 | 2018 | 743 | 0.450 |
Why?
|
Benzimidazoles | 1 | 2018 | 861 | 0.410 |
Why?
|
Androgen Antagonists | 2 | 2021 | 1411 | 0.410 |
Why?
|
Cervical Vertebrae | 2 | 2018 | 978 | 0.390 |
Why?
|
Pandemics | 10 | 2022 | 8729 | 0.360 |
Why?
|
Pyridines | 3 | 2020 | 2888 | 0.350 |
Why?
|
Lordosis | 2 | 2018 | 100 | 0.350 |
Why?
|
Lymphatic Diseases | 1 | 2022 | 318 | 0.350 |
Why?
|
Therapies, Investigational | 1 | 2021 | 110 | 0.340 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 257 | 0.330 |
Why?
|
Humans | 93 | 2023 | 766432 | 0.330 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 326 | 0.320 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 161 | 0.310 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 102 | 0.310 |
Why?
|
Radiography | 6 | 2020 | 6967 | 0.310 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3109 | 0.310 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3231 | 0.300 |
Why?
|
Crohn Disease | 2 | 2019 | 2285 | 0.300 |
Why?
|
Spinal Curvatures | 1 | 2018 | 74 | 0.290 |
Why?
|
Early Detection of Cancer | 3 | 2021 | 3236 | 0.290 |
Why?
|
Acetabulum | 2 | 2020 | 543 | 0.290 |
Why?
|
Femur | 2 | 2018 | 1318 | 0.290 |
Why?
|
Thigh | 1 | 2018 | 236 | 0.280 |
Why?
|
Immunologic Factors | 3 | 2021 | 1594 | 0.280 |
Why?
|
Piperazines | 1 | 2018 | 2546 | 0.280 |
Why?
|
Interleukin-8 | 1 | 2020 | 701 | 0.280 |
Why?
|
Fixation, Ocular | 1 | 2018 | 243 | 0.270 |
Why?
|
Foot Deformities | 1 | 2016 | 35 | 0.270 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2019 | 877 | 0.260 |
Why?
|
Lebanon | 5 | 2019 | 246 | 0.260 |
Why?
|
Postural Balance | 1 | 2020 | 637 | 0.250 |
Why?
|
Spinal Cord Diseases | 1 | 2018 | 291 | 0.250 |
Why?
|
Pelvic Bones | 1 | 2017 | 274 | 0.250 |
Why?
|
Lower Extremity | 3 | 2020 | 1217 | 0.250 |
Why?
|
Healthcare Disparities | 3 | 2021 | 3403 | 0.240 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2023 | 3508 | 0.240 |
Why?
|
Algorithms | 2 | 2021 | 14071 | 0.230 |
Why?
|
Tomography, Spiral Computed | 1 | 2016 | 273 | 0.230 |
Why?
|
Joints | 1 | 2016 | 324 | 0.230 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2928 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2022 | 4652 | 0.230 |
Why?
|
Immunoconjugates | 1 | 2022 | 976 | 0.220 |
Why?
|
Gait Disorders, Neurologic | 1 | 2016 | 244 | 0.220 |
Why?
|
Body Mass Index | 3 | 2021 | 13045 | 0.220 |
Why?
|
Tumor Microenvironment | 3 | 2022 | 3943 | 0.220 |
Why?
|
Thoracic Vertebrae | 1 | 2018 | 614 | 0.220 |
Why?
|
Urban Population | 1 | 2022 | 2038 | 0.220 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1609 | 0.220 |
Why?
|
Infection Control | 1 | 2020 | 984 | 0.210 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2022 | 8619 | 0.210 |
Why?
|
Male | 43 | 2023 | 363975 | 0.210 |
Why?
|
Young Adult | 18 | 2020 | 59928 | 0.200 |
Why?
|
Retreatment | 2 | 2020 | 596 | 0.200 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 1226 | 0.200 |
Why?
|
Joint Diseases | 1 | 2016 | 461 | 0.200 |
Why?
|
Female | 40 | 2023 | 396354 | 0.190 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1342 | 0.190 |
Why?
|
Prostatic Neoplasms | 3 | 2021 | 11094 | 0.190 |
Why?
|
Upper Extremity | 1 | 2016 | 684 | 0.180 |
Why?
|
Nephrectomy | 3 | 2022 | 928 | 0.180 |
Why?
|
Rural Population | 1 | 2022 | 2317 | 0.180 |
Why?
|
Tomography, X-Ray Computed | 7 | 2022 | 20706 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9401 | 0.170 |
Why?
|
Survival Analysis | 4 | 2021 | 10092 | 0.170 |
Why?
|
Anilides | 2 | 2020 | 413 | 0.170 |
Why?
|
Aged | 25 | 2023 | 171234 | 0.170 |
Why?
|
Retrospective Studies | 19 | 2023 | 81588 | 0.170 |
Why?
|
Functional Laterality | 1 | 2016 | 2243 | 0.170 |
Why?
|
Clinical Trials as Topic | 5 | 2021 | 8042 | 0.170 |
Why?
|
Range of Motion, Articular | 1 | 2016 | 1597 | 0.170 |
Why?
|
Protein Kinase Inhibitors | 4 | 2022 | 5696 | 0.170 |
Why?
|
Middle Aged | 25 | 2023 | 223127 | 0.170 |
Why?
|
Sexual Behavior | 1 | 2019 | 2192 | 0.170 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 26294 | 0.160 |
Why?
|
Movement | 1 | 2016 | 1468 | 0.160 |
Why?
|
Hip Joint | 1 | 2016 | 1017 | 0.160 |
Why?
|
Adult | 24 | 2022 | 223253 | 0.160 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 211 | 0.160 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7607 | 0.160 |
Why?
|
Parenteral Nutrition, Total | 1 | 2019 | 304 | 0.150 |
Why?
|
Sarcoma | 1 | 2019 | 1802 | 0.150 |
Why?
|
Outpatients | 1 | 2016 | 1595 | 0.150 |
Why?
|
Antibodies, Monoclonal | 3 | 2022 | 9243 | 0.150 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2505 | 0.140 |
Why?
|
Adolescent | 14 | 2020 | 88898 | 0.140 |
Why?
|
Medical Oncology | 3 | 2022 | 2340 | 0.140 |
Why?
|
Enterobacteriaceae Infections | 1 | 2019 | 190 | 0.140 |
Why?
|
Cohort Studies | 7 | 2023 | 41703 | 0.130 |
Why?
|
Femur Neck | 1 | 2018 | 316 | 0.130 |
Why?
|
Aged, 80 and over | 13 | 2021 | 59538 | 0.130 |
Why?
|
Liver Failure | 1 | 2018 | 252 | 0.130 |
Why?
|
Biomedical Research | 1 | 2022 | 3458 | 0.130 |
Why?
|
Muscle, Skeletal | 2 | 2018 | 4966 | 0.130 |
Why?
|
Combined Modality Therapy | 4 | 2020 | 8536 | 0.130 |
Why?
|
DNA Methylation | 1 | 2020 | 4428 | 0.130 |
Why?
|
Carrier State | 1 | 2019 | 530 | 0.120 |
Why?
|
Multiple Organ Failure | 2 | 2023 | 389 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 352 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2021 | 1755 | 0.120 |
Why?
|
Platelet Count | 1 | 2017 | 784 | 0.120 |
Why?
|
Melanoma | 1 | 2023 | 5699 | 0.110 |
Why?
|
Taxoids | 1 | 2017 | 665 | 0.110 |
Why?
|
Drug Utilization | 1 | 2020 | 1187 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2020 | 303 | 0.110 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 561 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 10379 | 0.110 |
Why?
|
Palliative Care | 2 | 2019 | 3640 | 0.110 |
Why?
|
Anthropometry | 1 | 2018 | 1336 | 0.110 |
Why?
|
Leukocyte Count | 1 | 2017 | 1606 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4418 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2019 | 1468 | 0.100 |
Why?
|
Renal Insufficiency | 1 | 2018 | 810 | 0.100 |
Why?
|
Computer Simulation | 1 | 2016 | 6259 | 0.100 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5367 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2019 | 638 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2022 | 15897 | 0.100 |
Why?
|
Methotrexate | 1 | 2019 | 1719 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2018 | 2426 | 0.100 |
Why?
|
Oxygen Consumption | 1 | 2018 | 1870 | 0.100 |
Why?
|
Tennessee | 1 | 2021 | 123 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1120 | 0.100 |
Why?
|
Health Facilities | 2 | 2022 | 578 | 0.100 |
Why?
|
Neutrophils | 2 | 2020 | 3782 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11217 | 0.090 |
Why?
|
Angiotensin I | 1 | 2021 | 47 | 0.090 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13486 | 0.090 |
Why?
|
Genomics | 4 | 2022 | 5924 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2020 | 20129 | 0.090 |
Why?
|
Censuses | 1 | 2022 | 197 | 0.090 |
Why?
|
Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 33 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 1105 | 0.090 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5389 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2018 | 21157 | 0.090 |
Why?
|
Risk Factors | 6 | 2022 | 74828 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2017 | 4888 | 0.090 |
Why?
|
Joint Instability | 2 | 2018 | 803 | 0.090 |
Why?
|
Cause of Death | 3 | 2022 | 3714 | 0.080 |
Why?
|
Reference Values | 2 | 2017 | 4913 | 0.080 |
Why?
|
Respiratory Insufficiency | 1 | 2018 | 1241 | 0.080 |
Why?
|
Indoles | 1 | 2018 | 1832 | 0.080 |
Why?
|
Cell Cycle | 1 | 2018 | 2925 | 0.080 |
Why?
|
Cross Infection | 1 | 2019 | 1427 | 0.080 |
Why?
|
Postoperative Period | 2 | 2019 | 1824 | 0.080 |
Why?
|
Lymphocytes | 1 | 2017 | 2605 | 0.080 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2021 | 324 | 0.080 |
Why?
|
Pyrimidines | 2 | 2018 | 3047 | 0.080 |
Why?
|
Case-Control Studies | 3 | 2017 | 22245 | 0.080 |
Why?
|
Gene Fusion | 1 | 2022 | 357 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6327 | 0.080 |
Why?
|
Drugs, Investigational | 1 | 2021 | 211 | 0.080 |
Why?
|
Telemedicine | 2 | 2020 | 3110 | 0.080 |
Why?
|
Survival Rate | 3 | 2020 | 12825 | 0.080 |
Why?
|
Mutation | 3 | 2021 | 30220 | 0.080 |
Why?
|
Ligases | 1 | 2020 | 330 | 0.080 |
Why?
|
Anatomy, Comparative | 1 | 2017 | 4 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 559 | 0.080 |
Why?
|
Calcaneus | 1 | 2020 | 144 | 0.080 |
Why?
|
Sulfonamides | 1 | 2018 | 1978 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2021 | 1881 | 0.070 |
Why?
|
Angiotensin II | 1 | 2021 | 844 | 0.070 |
Why?
|
Condoms | 1 | 2019 | 336 | 0.070 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 249 | 0.070 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 735 | 0.070 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2021 | 455 | 0.070 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2660 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2023 | 2511 | 0.070 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9101 | 0.070 |
Why?
|
Syphilis | 1 | 2019 | 243 | 0.070 |
Why?
|
Foot Joints | 1 | 2016 | 34 | 0.070 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 9611 | 0.070 |
Why?
|
Treatment Outcome | 6 | 2020 | 65202 | 0.070 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2329 | 0.070 |
Why?
|
Hydroxychloroquine | 2 | 2020 | 427 | 0.060 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 756 | 0.060 |
Why?
|
Foot | 1 | 2020 | 576 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3616 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1058 | 0.060 |
Why?
|
Bone Density | 1 | 2018 | 3491 | 0.060 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6306 | 0.060 |
Why?
|
Students, Medical | 1 | 2019 | 1962 | 0.060 |
Why?
|
Rotation | 1 | 2017 | 514 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1511 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12061 | 0.060 |
Why?
|
DNA Helicases | 1 | 2020 | 853 | 0.060 |
Why?
|
Prospective Studies | 5 | 2022 | 54826 | 0.060 |
Why?
|
Receptors, Androgen | 1 | 2021 | 1089 | 0.060 |
Why?
|
Biopsy | 2 | 2021 | 6778 | 0.060 |
Why?
|
Transcription Factors | 3 | 2021 | 12147 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3664 | 0.060 |
Why?
|
Organ Size | 1 | 2018 | 2261 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12807 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4356 | 0.050 |
Why?
|
HIV Infections | 1 | 2019 | 17534 | 0.050 |
Why?
|
International Cooperation | 1 | 2019 | 1434 | 0.050 |
Why?
|
Colonoscopy | 1 | 2021 | 1409 | 0.050 |
Why?
|
Prognosis | 4 | 2020 | 29922 | 0.050 |
Why?
|
Interleukin-7 | 1 | 2022 | 146 | 0.050 |
Why?
|
Accidental Falls | 1 | 2020 | 1078 | 0.050 |
Why?
|
Child | 5 | 2018 | 80668 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2021 | 2463 | 0.050 |
Why?
|
Electromyography | 1 | 2016 | 1398 | 0.050 |
Why?
|
Observer Variation | 1 | 2017 | 2613 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1897 | 0.040 |
Why?
|
Tumor Suppressor Proteins | 2 | 2021 | 2799 | 0.040 |
Why?
|
Diet | 1 | 2018 | 8085 | 0.040 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2727 | 0.040 |
Why?
|
Georgia | 1 | 2020 | 186 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2019 | 3552 | 0.040 |
Why?
|
Mammography | 1 | 2021 | 2430 | 0.040 |
Why?
|
Databases, Factual | 2 | 2020 | 8061 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 2935 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2018 | 6212 | 0.040 |
Why?
|
Odds Ratio | 1 | 2022 | 9654 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2021 | 526 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 370 | 0.040 |
Why?
|
Azithromycin | 1 | 2020 | 201 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 234 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 646 | 0.040 |
Why?
|
Preceptorship | 1 | 2019 | 57 | 0.040 |
Why?
|
Diaphyses | 1 | 2018 | 65 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 533 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2021 | 5129 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2022 | 3798 | 0.040 |
Why?
|
Massachusetts | 1 | 2021 | 8885 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 703 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2020 | 328 | 0.040 |
Why?
|
Femur Head | 1 | 2018 | 297 | 0.030 |
Why?
|
Indazoles | 1 | 2018 | 306 | 0.030 |
Why?
|
Macrophages | 1 | 2021 | 5782 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11059 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1441 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2470 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 904 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5334 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 698 | 0.030 |
Why?
|
Registries | 1 | 2022 | 8344 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1384 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5794 | 0.030 |
Why?
|
Mass Screening | 1 | 2021 | 5451 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 997 | 0.030 |
Why?
|
Quality Improvement | 1 | 2020 | 3849 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2018 | 433 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1010 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2020 | 1251 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1117 | 0.030 |
Why?
|
Heart Failure | 1 | 2018 | 11816 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1732 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3357 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 857 | 0.030 |
Why?
|
Time Factors | 3 | 2020 | 40116 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1319 | 0.030 |
Why?
|
Universities | 1 | 2019 | 1005 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2020 | 4879 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2021 | 1203 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2668 | 0.030 |
Why?
|
Prevalence | 1 | 2019 | 15820 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2038 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2059 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2020 | 2158 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1279 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2020 | 2056 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3434 | 0.020 |
Why?
|
United States | 2 | 2022 | 72910 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39283 | 0.020 |
Why?
|
Animals | 2 | 2021 | 168887 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6508 | 0.020 |
Why?
|
Quality of Life | 1 | 2019 | 13472 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4348 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2020 | 3068 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2018 | 6845 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9333 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8478 | 0.020 |
Why?
|
Hemorrhage | 1 | 2018 | 3460 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10614 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2020 | 5337 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10579 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 7057 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9521 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7840 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7071 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18395 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 24272 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2018 | 11501 | 0.010 |
Why?
|
Signal Transduction | 1 | 2021 | 23611 | 0.010 |
Why?
|